President Trump calls new drug pricing deal 'the biggest thing ever'

The White House announced an agreement with nine major drugmakers (Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead, GSK, Merck, Novartis and Sanofi) to give all 50 state Medicaid programs access to “most-favored-nation” pricing tied to the lowest prices in other developed countries and to apply the model to new innovative medicines. In exchange the companies pledged at least $150 billion of U.S. investment in manufacturing/R&D, donations to a Strategic Active Pharmaceutical Ingredients Reserve, direct-to-consumer deep discounts via a new TrumpRx platform planned for January, and relief from potential future tariffs; critics and policy experts warn implementation details are unclear and question whether savings will materialize. The announcement increases regulatory and political risk for U.S. pharma pricing and revenues if enacted, while creating potential supply-chain and trade implications abroad.

Analysis

Market structure: The announced MFN-style accords and TrumpRx compress pricing power for high-volume branded drugs sold to Medicaid and direct-to-consumer channels, disproportionately hurting large-margin specialty franchises. Direct losers: AMGN, GILD, NVS (higher Medicaid exposure and concentrated flagship drugs); relative winners: PFE, AZN, SNY and GSK (more diversified portfolios, vaccine/consumer balance) and industrial suppliers if the $150B capex materializes. Expect 5–15% downside to FY revenue on high-Medicaid drugs in worst-case modeled scenarios over 12–24 months, with EBITDA contraction concentrated in affected franchises.

Risk assessment: Tail risks include legal injunctions (favorable to pharma), CMS rulemaking that narrows MFN scope, or retaliatory foreign pricing/ trade responses that reduce global pricing power. Time map: headlines move equities in days; earnings guidance and Medicaid uptake drive weeks–months; structural margin and R&D allocation shifts play out over 12–36 months. Hidden dependencies: impact is highly sensitive to MFN index methodology, state adoption rates, and which NDCs are included — an adverse CMS definition could halve modeled revenue hits.

Trade implications: Tactical plays include short-biotech/brand concentration (AMGN, GILD) and long diversified large-cap pharm (PFE, AZN) plus select industrial suppliers if capex confirmations arrive. Options: buy 6–9 month puts on AMGN and GILD ~15% OTM sized to 1–2% portfolio risk; pair trade long PFE (3% notional) / short AMGN (2% notional) for relative safety. Time entry 0–6 weeks ahead of quarterly reports and the planned January TrumpRx rollout; trim/exit on confirmatory CMS guidance or material legal rulings.

Key Decisions for Investors

• Initiate a tactical short on AMGN: establish a 2% portfolio notional short or buy 6–9 month AMGN puts ~15% OTM sized to 1.5% portfolio risk, exit/trim on confirmatory CMS guidance or if AMGN revises guidance positively.
• Establish a relative-long in PFE and AZN: allocate 3% notional to PFE (buy stock or 6–9 month calls if preferred) and 2% to AZN as defensive pharma exposure; use these as the long leg in pair trades vs short AMGN/GILD.
• Buy protection on GILD: purchase 6–9 month GILD puts ~15–25% OTM sized to 1% portfolio as insurance against concentrated-revenue hits; consider widening strike if realized volatility spikes >30%.
• Rotate 4–6% from small-cap biotech into industrials/chemicals suppliers: after public confirmations of capex plans (monitor company announcements for $150B allocation details over next 30–90 days), reallocate into industrial machinery/chemical names with direct pharma exposure.
• Trigger-based rule: monitor three near-term catalysts and act: (1) CMS publication of MFN calculation within 30–60 days — if narrow, close shorts by 50%; (2) state Medicaid enrollment/uptake over next 90 days — if low, reduce hedges; (3) any court injunction — buy back shorts immediately.